Bluprynt | $4,250,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
NextPoint Therapeutics, Inc.
- 15/02/2024
- Series B
- $42,500,000
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
- Industry Biotechnology
- Website https://nextpointtx.com/
- LinkedIn https://www.linkedin.com/company/nextpoint-therapeutics/
Related People
Ivan CheungFounder
United States -
Scarsdale, New York
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
JetScale AI | $5,400,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Jest | $7,000,000 | (Feb 27, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)